Next Generation News and Research

RSS

MAQUET Cardiovascular launches VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting System

MAQUET Cardiovascular today announced the launch of its VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting (EVH) System, which utilizes next-generation HEMOPRO cut-and-seal technology to reduce thermal spread and to achieve optimal conduit quality for coronary artery bypass graft (CABG) surgery patients. The minimally invasive VASOVIEW HEMOPRO 2 system is an example of MAQUET Cardiovascular's commitment to EVH, and technologies that promote the highest level of conduit quality.

27 Jul 2010

KIKA Clinical Solutions reports 47% increase in service bookings during first-half of 2010

KIKA™ Clinical Solutions is on track for unprecedented 2010 growth. KIKA is the leading provider of advanced EDC solutions for Clinical Asset Management™ for the pharmaceutical, biotechnology and medical device markets.

26 Jul 2010

Calibra Medical's Finesse insulin patch-pen receives FDA clearance for use with Novo Nordisk's Novolog

Calibra Medical announced today it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Finesse™ insulin patch-pen for up to three-day use with Novo Nordisk's Novolog® rapid acting insulin. Combining the mealtime therapy-adherence benefits of insulin pumps with the simplicity and affordability of syringes and pens, Calibra's novel bolus-only patch-pen is a small, adhesively attached, flat device that can be operated discretely through clothing to deliver mealtime, snack time, and correction bolus insulin in seconds.

26 Jul 2010

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Onyx Pharmaceuticals, Inc. today announced positive top-line results from the Phase 2b 003-A1 study of single-agent carfilzomib, a selective, next generation proteasome inhibitor, in patients with relapsed and refractory multiple myeloma.

26 Jul 2010

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

Asuragen, Inc. announced today the results from two collaborative studies, one with the University of California Davis M.I.N.D. Institute and another with Rush University Medical Center, that demonstrate comprehensive molecular profiling of the Fragile X Mental Retardation (FMR1) gene using advanced PCR-based methods.

26 Jul 2010

British adults support removal of tobacco displays in shops, ban on cigarette vending machines: Survey

Three quarters of British adults support the removal of shop displays of tobacco (73 per cent) and a complete ban on cigarette vending machines (77 per cent) according to a new survey commissioned by Cancer Research UK this weekend.

26 Jul 2010

New model of inflammatory bowel disease explores interactions of cells in immune system

Scientists at the Virginia Bioinformatics Institute at Virginia Tech have constructed a mathematical and computational model of inflammatory bowel disease that allows researchers to simulate the cellular and molecular changes underlying chronic inflammation in humans. The model allows scientists to explore different interactions of cells in the immune system, check how these cells are linked to inflammation in the colon, and identify intervention points to perhaps stop the disease in its tracks.

23 Jul 2010

Euthymics Bioscience completes $24 million Series A financing

Euthymics Bioscience, Inc., a clinical-stage company developing next-generation antidepressants, today announced the completion of a Series A financing -- led by Novartis Venture Funds and Venture Investors - for a total investment commitment of $24 million in milestone-conditioned tranches. Hambrecht & Quist Capital Management, LLC, GBS Venture Partners and the State of Wisconsin Investment Board also participated in the financing.

22 Jul 2010

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

In a joint study, scientists from The Scripps Research Institute and the Dana-Farber Cancer Institute at Harvard University have uncovered a novel mechanism that dramatically increases insulin sensitivity and reduces the risk of developing type 2 diabetes and cardiovascular disease.

22 Jul 2010

UMHS selects Epic Systems for medical information technology overhaul

The University of Michigan Health System has just embarked on a multi-year journey to completely transform the way its physicians, nurses, other care providers and administrators use information technology in every U-M hospital, clinic and office.

22 Jul 2010

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).

21 Jul 2010

Next generation robot could eliminate 'the doctor'

As physician-guided robots routinely operate on patients at most major hospitals, the next generation robot could eliminate a surprising element from that scenario -- the doctor.

21 Jul 2010

Clinical research updates on interventional cardiology techniques that affect patient care

TCT 2010 will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.

21 Jul 2010

INRA Genomic Platform core facility now provides services on Fluidigm's BioMark System for Genetic Analysis

Fluidigm Corporation today announced that the Toulouse Midi-Pyrénées Genomic Platform - Genotoul INRA core facility is now providing a wide range of services on a BioMark™ System for Genetic Analysis to a wide range of French researchers. These services include SNP genotyping, gene expression analysis and digital PCR quantification of DNA libraries for next-generation sequencing. The INRA has been validating the performance of the system on several projects over the past year.

21 Jul 2010

Health experts and Republicans push for biosimilar drug clinical trials

The Hill: On Monday, experts warned during a Capitol Hill discussion hosted by the Congressional Health Care Caucus that "the absence of mandatory clinical trials for biosimilar drugs could compromise their safety and effectiveness." The recently passed health reform law "outlined a pathway for the Food and Drug Administration (FDA) to approve next-generation biopharmaceuticals modeled on original breakthrough drugs.

21 Jul 2010

FDA accepts MannKind's resubmission of AFREZZA NDA, sets PDUFA action date

MannKind Corporation today announced that it has submitted, and the U.S. Food and Drug Administration has accepted, MannKind's resubmission of its New Drug Application for AFREZZA™ (insulin human [rDNA origin]) and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act action date of December 29, 2010.

21 Jul 2010

New development in flu prevention & treatment

In a groundbreaking development, scientists at the Australian National University in Canberra have found the key to the mutation of the flu virus. This may allow the manufacturing of a life-long vaccine stopping the need for repeated vaccinations. The scientists reveal that they have found a protein in the virus that changes or mutates in order to develop resistance in the virus.

20 Jul 2010

MedeAnalytics 10 software platform released

MedeAnalytics, a leading provider of healthcare performance management solutions, today announced its summer 2010 software platform release, MedeAnalytics 10, which offers performance-packed features for proactive alerting and outlier analysis. The release incorporates client input and reflects the company's ongoing investment in its analytic platform. New releases are provided to clients on a semi-annual basis and typically require no upgrades or installations.

20 Jul 2010

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

Johnson & Johnson today announced sales of $15.3 billion for the second quarter of 2010, an increase of 0.6% as compared to the second quarter of 2009. Operational results increased 0.1% and the positive impact of currency was 0.5%. Domestic sales declined 2.8%, while international sales increased 4.1%, reflecting operational growth of 3.0% and a positive currency impact of 1.1%.

20 Jul 2010

NanoViricides presents study results of nanoviricides anti-Ebola agents

NanoViricides, Inc. reports that the results of the evaluation of several of its nanoviricides anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

20 Jul 2010

Next Generation News and Research

MAQUET Cardiovascular launches VASOVIEW HEMOPRO 2 Endoscopic Vessel Harvesting System

KIKA Clinical Solutions reports 47% increase in service bookings during first-half of 2010

Calibra Medical's Finesse insulin patch-pen receives FDA clearance for use with Novo Nordisk's Novolog

Onyx reports positive results from carfilzomib Phase 2b 003-A1 study in multiple myeloma

Asuragen reports collaborative study results of advanced PCR-based molecular profiling of FMR1 gene

British adults support removal of tobacco displays in shops, ban on cigarette vending machines: Survey

New model of inflammatory bowel disease explores interactions of cells in immune system

Euthymics Bioscience completes $24 million Series A financing

Scientists uncover new mechanism that reduces risk of type 2 diabetes, cardiovascular disease

UMHS selects Epic Systems for medical information technology overhaul

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

Next generation robot could eliminate 'the doctor'

Clinical research updates on interventional cardiology techniques that affect patient care

INRA Genomic Platform core facility now provides services on Fluidigm's BioMark System for Genetic Analysis

Health experts and Republicans push for biosimilar drug clinical trials

FDA accepts MannKind's resubmission of AFREZZA NDA, sets PDUFA action date

New development in flu prevention & treatment

MedeAnalytics 10 software platform released

Johnson & Johnson second-quarter sales increase 0.6% to $15.3 billion

NanoViricides presents study results of nanoviricides anti-Ebola agents

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News